Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Diversify into RBI-regulated P2P lending platforms and earn up to 11.5% p.a.
Invest in curated
corporate, gold, and govt. bonds
Earn income
while helping India move to clean energy
Connect with investors, share insights, and grow together.
Master the world of Alternative Investments with our in-depth courses
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning.
Read about our journey and get to know the leadership team at Vested
Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as needed treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Its pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage. more
Time Frame | NEUP | S&P500 | |
---|---|---|---|
1-Week Return | 5.33%% | % | 1.53%% |
1-Month Return | 54.38%% | % | 4.75%% |
3-Month Return | 29.86%% | % | 2.77%% |
6-Month Return | -27.01%% | % | 12.18%% |
1-Year Return | -68.33%% | % | 22.34%% |
3-Year Return | -96.15%% | % | 38.91%% |
5-Year Return | -97.21%% | % | 80.7%% |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NEUP | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NEUP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
EV/R | 0.00 |
EV/Ebitda | NM |
Bionomics Ltd (NEUP) share price today is $4.94
Yes, Indians can buy shares of Bionomics Ltd (NEUP) on Vested. To buy Bionomics Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NEUP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Bionomics Ltd (NEUP) via the Vested app. You can start investing in Bionomics Ltd (NEUP) with a minimum investment of $1.
You can invest in shares of Bionomics Ltd (NEUP) via Vested in three simple steps:
The 52-week high price of Bionomics Ltd (NEUP) is $15.72. The 52-week low price of Bionomics Ltd (NEUP) is $2.12.
The price-to-book (P/B) ratio of Bionomics Ltd (NEUP) is 0.00
The market capitalization of Bionomics Ltd (NEUP) is $17.36B
The stock symbol (or ticker) of Bionomics Ltd is NEUP